Copyright Reports & Markets. All rights reserved.

Global Giant Cell Arteritis Therapeutic Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Giant Cell Arteritis Therapeutic by Type
    • 1.3.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type in 2025
    • 1.3.3 Prednisone
    • 1.3.4 Methotrexate
    • 1.3.5 Tocilizumab
    • 1.3.6 Aspirin
  • 1.4 Global Giant Cell Arteritis Therapeutic Market by Application
    • 1.4.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Corticosteroids
    • 1.4.3 Immunosuppressive Agents
    • 1.4.4 Anticoagulants
    • 1.4.5 Others
  • 1.5 Global Giant Cell Arteritis Therapeutic Market Size & Forecast
  • 1.6 Global Giant Cell Arteritis Therapeutic Market Size and Forecast by Region
    • 1.6.1 Global Giant Cell Arteritis Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Giant Cell Arteritis Therapeutic Market Size by Region, (2021-2032)
    • 1.6.3 North America Giant Cell Arteritis Therapeutic Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Giant Cell Arteritis Therapeutic Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size and Prospect (2021-2032)
    • 1.6.6 South America Giant Cell Arteritis Therapeutic Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Sanofi
    • 2.1.1 Sanofi Details
    • 2.1.2 Sanofi Major Business
    • 2.1.3 Sanofi Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.1.4 Sanofi Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Sanofi Recent Developments and Future Plans
  • 2.2 Kiniksa Pharmaceuticals, Ltd.
    • 2.2.1 Kiniksa Pharmaceuticals, Ltd. Details
    • 2.2.2 Kiniksa Pharmaceuticals, Ltd. Major Business
    • 2.2.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.2.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments and Future Plans
  • 2.3 Regeneron
    • 2.3.1 Regeneron Details
    • 2.3.2 Regeneron Major Business
    • 2.3.3 Regeneron Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.3.4 Regeneron Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Regeneron Recent Developments and Future Plans
  • 2.4 GlaxoSmithKline plc
    • 2.4.1 GlaxoSmithKline plc Details
    • 2.4.2 GlaxoSmithKline plc Major Business
    • 2.4.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.4.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 GlaxoSmithKline plc Recent Developments and Future Plans
  • 2.5 F. Hoffmann-La Roche Ltd.
    • 2.5.1 F. Hoffmann-La Roche Ltd. Details
    • 2.5.2 F. Hoffmann-La Roche Ltd. Major Business
    • 2.5.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.5.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
  • 2.6 Novartis AG
    • 2.6.1 Novartis AG Details
    • 2.6.2 Novartis AG Major Business
    • 2.6.3 Novartis AG Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.6.4 Novartis AG Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Novartis AG Recent Developments and Future Plans
  • 2.7 AbbVie, Inc.
    • 2.7.1 AbbVie, Inc. Details
    • 2.7.2 AbbVie, Inc. Major Business
    • 2.7.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.7.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 AbbVie, Inc. Recent Developments and Future Plans
  • 2.8 Bristol-Myers Squibb Company
    • 2.8.1 Bristol-Myers Squibb Company Details
    • 2.8.2 Bristol-Myers Squibb Company Major Business
    • 2.8.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.8.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
  • 2.9 Abbott
    • 2.9.1 Abbott Details
    • 2.9.2 Abbott Major Business
    • 2.9.3 Abbott Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.9.4 Abbott Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Abbott Recent Developments and Future Plans
  • 2.10 Johnson & Johnson Services, Inc.
    • 2.10.1 Johnson & Johnson Services, Inc. Details
    • 2.10.2 Johnson & Johnson Services, Inc. Major Business
    • 2.10.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.10.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Johnson & Johnson Services, Inc. Recent Developments and Future Plans
  • 2.11 Johns Hopkins Hospital
    • 2.11.1 Johns Hopkins Hospital Details
    • 2.11.2 Johns Hopkins Hospital Major Business
    • 2.11.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.11.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Johns Hopkins Hospital Recent Developments and Future Plans
  • 2.12 Fortis Healthcare
    • 2.12.1 Fortis Healthcare Details
    • 2.12.2 Fortis Healthcare Major Business
    • 2.12.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.12.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Fortis Healthcare Recent Developments and Future Plans
  • 2.13 American College of Rheumatology
    • 2.13.1 American College of Rheumatology Details
    • 2.13.2 American College of Rheumatology Major Business
    • 2.13.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.13.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 American College of Rheumatology Recent Developments and Future Plans
  • 2.14 Duke University Health System
    • 2.14.1 Duke University Health System Details
    • 2.14.2 Duke University Health System Major Business
    • 2.14.3 Duke University Health System Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.14.4 Duke University Health System Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Duke University Health System Recent Developments and Future Plans
  • 2.15 Lahey Clinic Foundation
    • 2.15.1 Lahey Clinic Foundation Details
    • 2.15.2 Lahey Clinic Foundation Major Business
    • 2.15.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product and Solutions
    • 2.15.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Lahey Clinic Foundation Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Giant Cell Arteritis Therapeutic Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Giant Cell Arteritis Therapeutic by Company Revenue
    • 3.2.2 Top 3 Giant Cell Arteritis Therapeutic Players Market Share in 2025
    • 3.2.3 Top 6 Giant Cell Arteritis Therapeutic Players Market Share in 2025
  • 3.3 Giant Cell Arteritis Therapeutic Market: Overall Company Footprint Analysis
    • 3.3.1 Giant Cell Arteritis Therapeutic Market: Region Footprint
    • 3.3.2 Giant Cell Arteritis Therapeutic Market: Company Product Type Footprint
    • 3.3.3 Giant Cell Arteritis Therapeutic Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Giant Cell Arteritis Therapeutic Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2021-2032)
  • 6.2 North America Giant Cell Arteritis Therapeutic Market Size by Application (2021-2032)
  • 6.3 North America Giant Cell Arteritis Therapeutic Market Size by Country
    • 6.3.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2021-2032)
    • 6.3.2 United States Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2021-2032)
  • 7.2 Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2021-2032)
  • 7.3 Europe Giant Cell Arteritis Therapeutic Market Size by Country
    • 7.3.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 7.3.3 France Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size by Region
    • 8.3.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2021-2032)
    • 8.3.2 China Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 8.3.5 India Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2021-2032)
  • 9.2 South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2021-2032)
  • 9.3 South America Giant Cell Arteritis Therapeutic Market Size by Country
    • 9.3.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Country
    • 10.3.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Giant Cell Arteritis Therapeutic Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Giant Cell Arteritis Therapeutic Market Drivers
  • 11.2 Giant Cell Arteritis Therapeutic Market Restraints
  • 11.3 Giant Cell Arteritis Therapeutic Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Giant Cell Arteritis Therapeutic Industry Chain
  • 12.2 Giant Cell Arteritis Therapeutic Upstream Analysis
  • 12.3 Giant Cell Arteritis Therapeutic Midstream Analysis
  • 12.4 Giant Cell Arteritis Therapeutic Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Giant Cell Arteritis Therapeutic market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.
    This report is a detailed and comprehensive analysis for global Giant Cell Arteritis Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Giant Cell Arteritis Therapeutic market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Giant Cell Arteritis Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Giant Cell Arteritis Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Giant Cell Arteritis Therapeutic market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Giant Cell Arteritis Therapeutic
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Giant Cell Arteritis Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie, Inc., Bristol-Myers Squibb Company, Abbott, Johnson & Johnson Services, Inc., etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Giant Cell Arteritis Therapeutic market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Prednisone
    Methotrexate
    Tocilizumab
    Aspirin
    Market segment by Application
    Corticosteroids
    Immunosuppressive Agents
    Anticoagulants
    Others
    Market segment by players, this report covers
    Sanofi
    Kiniksa Pharmaceuticals, Ltd.
    Regeneron
    GlaxoSmithKline plc
    F. Hoffmann-La Roche Ltd.
    Novartis AG
    AbbVie, Inc.
    Bristol-Myers Squibb Company
    Abbott
    Johnson & Johnson Services, Inc.
    Johns Hopkins Hospital
    Fortis Healthcare
    American College of Rheumatology
    Duke University Health System
    Lahey Clinic Foundation
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Giant Cell Arteritis Therapeutic product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Giant Cell Arteritis Therapeutic, with revenue, gross margin, and global market share of Giant Cell Arteritis Therapeutic from 2021 to 2026.
    Chapter 3, the Giant Cell Arteritis Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Giant Cell Arteritis Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Giant Cell Arteritis Therapeutic.
    Chapter 13, to describe Giant Cell Arteritis Therapeutic research findings and conclusion.

    Buy now